Sipuleucel-T in management of favorable-risk prostate cancer: the ProVent trial

At the end of last year, Dendreon announced that the Phase III ProVent trial of sipuelucel-T (Provenge) in the treatment of men with relatively lower-risk forms of prostate cancer (as compared to active surveillance) had been fully enrolled ahead of schedule. … READ MORE …

Jane Brody on prostate cancer in the NYT

Jane Brody is an experienced journalist who writes regularly about issues related to health care in The New York Times. Your sitemaster regularly reads her columns because she does her homework with care and provides sound information for her readers. … READ MORE …

A follow-up on active surveillance and the MEAL study

A couple of weeks ago, the full report on the Men’s Eating and Living (MEAL) study was published in the Journal of the American Medical Association. It has generated a lot of discussion, some of which is distinctly misguided. … READ MORE …

AS in practice in a specific US community setting

In a presentation at the ASCO annual meeting, Dr. Ronald Chen reported that just 32 percent of newly diagnosed men who were initially managed on active surveillance (AS) in North Carolina between 2011 and 2013 were actually managed in compliance with guideline recommended monitoring. … READ MORE …

What did we learn at the AUA this year?

The annual meeting of the American Urological Association (AUA) is one at which a great deal of information is exchanged, but a lot of that information is of limited utility to patients. … READ MORE …

Active surveillance at the EAU annual meeting

Active surveillance and its role in the management of lower-risk forms of prostate cancer, and related issues like MRI scanning, were clearly key topics of attention at the annual meeting of the European Association of Urology in Barcelona over the weekend. … READ MORE …

Do men on AS need their own support groups?

Howard Wolinsky is a long-time prostate cancer patient who has been on active surveillance (AS) since his diagnosis in 2010, when one of his doctors described him as a “poster child” for active surveillance. … READ MORE …

Much more monitoring of lower risk prostate cancer in US since 2010

According to a brief research letter in the Journal of the American Medical Association this week, there was a major increase in the application of active surveillance (AS) and watchful waiting (WW) in first-line management of prostate cancer between 2010 and 2015. … READ MORE …

Diet, diagnosis, AS, and the management of lower-risk forms of prostate cancer

Over the years there has been a great deal of speculation (and a very small amount of data) suggesting that men who get diagnosed with relatively low-risk forms of prostate cancer may be able to delay progression of their disease by eating the right diet. … READ MORE …

Howard Wolinsky dodges another MRI and another biopsy

Under the heading “Rats, my PSA went up. Do I need another bleeping biopsy?” Howard Wolinsky provides us with the latest “lowdown” on his 8-year-long prostate cancer journey on active surveillance. … READ MORE …

Prognosis of patient progression and outcomes on active surveillance

The prostate cancer research team led by Dr. Peter Pinto at the National Cancer Institute has just published some interesting new information on risk for disease progression in men on active surveillance. … READ MORE …

Picking the right men for initial management on AS

At the recently completed Canadian Uro-oncology Summit in Toronto, Dr. Laurence Klotz gave a very thorough update on active surveillance (AS) and its application in the management of lower-risk forms of localized prostate cancer. … READ MORE …

Is anyone with intermediate-risk prostate cancer a “good” candidate for AS?

There is no longer any doubt that men initially diagnosed with low- and very low-risk forms of prostate cancer are, in most cases, either excellent or good candidates for first-line management on active surveillance (AS). … READ MORE …

Is PTEN loss a risk factor for progression of men on active surveillance?

A newly published paper in the journal Prostate Cancer and Prostatic Diseases has explored the above question based on data from the Johns Hopkins active surveillance (AS) cohort of men with initially low- or very low-risk prostate cancer. … READ MORE …

Anxiety and AS: a patient’s perspective

In his most recent commentary on living on active surveillance, journalist Howard Wolinsky writes about the issue of anxiety which can affect a significant subset of men who are appropriate candidates for active surveillance (AS) or who have difficulty staying on AS — particularly during their first two years of management using this technique. … READ MORE …